GHP Biotechnology Awards 2023 At the moment prospective clinical trials are ongoing. But supervised learning using support vector machine algorithms has given an accuracy of 92.3%. Mestastop’s third platform, METVivo®, is an efficient metastasis animal model platform that speeds up the generation of an animal model for in vivo testing. Mestastop has engineered cancer cells to make them more metastatic, and as a result, liver metastasis for colorectal cancer orthotopic models takes only six weeks. The company predicts that METVivo® will be particularly beneficial to biopharma companies working to identify new drugs to fight metastasis. As well as their primary functions, Mestastop’s proprietary platforms will help to assess the safety of medications that may have an adverse impact on metastasis. The company’s vision is to become the go-to specialist on metastasis. It plans to achieve this by dissecting complex metastasis biology for the first time with special emphasis on the unexplored. Looking to the future, Mestastop’s next mission is to use its proprietary platforms to address novel drug discovery and drug repurposing around metastasis. By identifying more metastasisspecific patterns in primary tumour samples of patients, the team plan to build a predictive algorithm for early metastasis diagnosis. Despite the scientific breakthroughs Mestastop continues to make, the company is still classed as a small biotech. Mestastop counts on the support of collaborators and investors to continue its life-saving research. By promoting the value and potential of METAssay®, METSCAN® and METVivo®, the company aims to demonstrate the value of its mission to potential investors and collaborators in the biotech industry. In Dr Arnab’s words, “At Mestastop we never want to lose sight of the fact that we are talking about real patients and their loved ones. Living with the uncertainty, emotional strain, and financial burden of cancer, is unbearable for millions of patients. That’s why we are working to empower the biopharma industry with these innovative platforms. We can provide tools to delay cancer’s progress. And the exciting news is that this is possible using existing drugs. There is no need to wait a decade for a new drug to come along.” To find out more, or to express your interest, please visit the company website. Contact: Dr Arnab Roy Chowdhury Company: MESTASTOP SOLUTIONS PVT LTD Web Address: https://mestastop.com/
RkJQdWJsaXNoZXIy MTUyMDQwMA==